Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum NOVADAQ TECHNOLOGIES INC. T.NDQ

"Novadaq Technologies Inc develops & commercializes medical imaging & therapeutic devices for use in the operating room. Its proprietary imaging platform can be used to visualize blood vessels, nerves & the lymphatic system during surgical procedures."

TSX:NDQ - Post Discussion

NOVADAQ TECHNOLOGIES INC. > Novadaq Technologies, Inc. Analyst Notes
View:
Post by factsfinder on Apr 05, 2014 9:57am

Novadaq Technologies, Inc. Analyst Notes

Novadaq Technologies, Inc. Analyst Notes

On March 25, 2014, Novadaq Technologies, Inc. (Novadaq) announced that it will be participating at the 13th Annual Needham Healthcare Conference. The Company stated that its Vice President of Corporate Development & Investor Relations, David Martin, is scheduled to present Novadaq's corporate overview on April 8, 2014 at 4:20 p.m. ET at the Westin Grand Central Hotel in New York. Novadaq added that the presentation will be webcast live and will also be archived for 90 days on the Company website. The full analyst notes on Novadaq Technologies, Inc. are available to download free of charge at:

https://www.AnalystsReview.com/04012014/NVDQ/report.pdf

Comment by dapperden on Jul 14, 2015 10:05pm
Info on NDQ-this is being touted by Stansberry Research, they have a 'PRO" hired that is saying this stock can be worth a 500% gainer or far more,because of their Pinpoint Surgery.The person who is making this claim is Paul Mampilly,who,at 45, has made a fortune on specs,He recommended NDQ at $12.40 a short time ago,and it has gone up over 30% since.Stansberry wants $2500 for joining and ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities